Hematologic Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Umbralisib: A Promising Therapy for Hematologic Malignancies - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Umbralisib: A Promising Therapy for Hematologic Malignancies 
Cancer Therapy Advisor
Umbralisib, a next-generation PI3K? inhibitor, may be a safe and effective option for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or Hodgkin/non-Hodgkin lymphomas, according to a study published in The Lancet Oncology.1 ...

and more » 


Should the General Population Be Screened for MGUS? - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Should the General Population Be Screened for MGUS? 
Cancer Therapy Advisor
Patients with particular abnormal proteins in their blood ? a condition known as monoclonal gammopathies of undetermined significance (MGUS) ? have a small, but persistent lifetime risk of multiple myeloma or other hematologic cancers. For more than ...

 


Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers - GlobeNewswire (press release)



GlobeNewswire (press release)
 
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers 
GlobeNewswire (press release)
?DLBCL is a rare hematologic cancer with few treatment options and the expansion of the Phase 2 trial provides the opportunity to further explore the broad treatment potential of CLR 131 in an area of significant unmet need. We are now exploring CLR ...

and more » 


Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and ... - Dove Medical Press



Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and ... 
Dove Medical Press
The tolerability profile of PARP inhibitors often includes hematologic toxicities, and the characterization of these adverse events is important to allow effective management by clinicians. Zhou et al1 recently carried out a meta-analysis of the ...

 


Pfizer Receives Positive CHMP Opinion for Two Hematology ... - Business Wire (press release)



Pfizer Receives Positive CHMP Opinion for Two Hematology ... 
Business Wire (press release)
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology medicines be ...

and more » 


Amgen Receives Positive Opinion Expanding Use Of XGEVA ... - Markets Insider



Amgen Receives Positive Opinion Expanding Use Of XGEVA ... 
Markets Insider
THOUSAND OAKS, Calif., Feb. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current ...

and more » 


Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients ... - Markets Insider



Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients ... 
Markets Insider
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on people living with cancer. Our growing pipeline of biologics, small molecules, and immunotherapies is focused on identifying and translating the best ...

and more » 


Dr. Seah Lim named hematology director at WMC Cancer Institute - Westfair Online



Westfair Online
 
Dr. Seah Lim named hematology director at WMC Cancer Institute 
Westfair Online
Board certified in hematology and internal medicine, Lim most recently served as director of hematology at Rhode Island Hospital and professor of medicine at Brown University's Warren Alpert Medical School. He has also held appointments in Pittsburgh ...

 


Survey May Help To Identify Patients With Cancer at Risk of HBV Reactivation - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Survey May Help To Identify Patients With Cancer at Risk of HBV Reactivation 
Cancer Therapy Advisor
A selective screening model may help to identify patients receiving anticancer treatment who are at risk of reactivating a hepatitis B virus (HBV) infection, according to research published in the Journal of Clinical Oncology.1. Patients with HBV ...

 


Pediatric CML: Imatinib Effective in the Front Line - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Pediatric CML: Imatinib Effective in the Front Line 
Cancer Therapy Advisor
First-line imatinib is effective and safe among pediatric patients with chronic myeloid leukemia (CML), according to a study being presented at the 2017 American Society of Hematology Annual Meeting (ASH) in Atlanta, Georgia.1. For the prospective CML ...